Published Date: 22 Apr 2023
The US News and World Report rankings, once the benchmark by which students evaluated medical schools, have recently begun to lose some of their sway. The value of a school can be evaluated in various ways, according to medical students.
Read Full NewsThree medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.
Despite FDA package insert recommendations, most patients with breast cancer who are prescribed CDK4/6 inhibitors do not receive liver function tests before starting treatment.
Patients who receive both standard medical treatment and complementary and alternative therapies have higher mortality — possibly due to reduced use of endocrine therapy and radiation.
1.
Survival improved with lobectomy, segmentectomy in early non-small cell lung cancer
2.
Through the activation of bitter taste receptors, lidocaine has the potential to kill some cancer cells.
3.
First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.
4.
A large study found that monolayers were superior in detecting cancer.
5.
Potentially Novel Approach for Treating Advanced Colorectal Cancer with KRAS Mutations.
1.
Does Lactate Signal Anemia? Exploring the Complexities of Hyperlactatemia and Red Blood Cell Health
2.
Lentigo Maligna Melanoma: Everything You Need To Know about This Skin Cancer
3.
New Anticoagulants: Balancing Efficacy and Safety in Patients with Atrial Fibrillation
4.
Unveiling the Hidden Dangers of Hand Cancer: How to Protect Yourself
5.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation